Cite
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
MLA
Pulsoni, Alessandro, et al. “Local Radiotherapy and Measurable Residual Disease-Driven Immunotherapy in Patients with Early-Stage Follicular Lymphoma (FIL MIRO): Final Results of a Prospective, Multicentre, Phase 2 Trial.” The Lancet. Haematology, vol. 11, no. 7, July 2024, pp. e499–509. EBSCOhost, https://doi.org/10.1016/S2352-3026(24)00143-1.
APA
Pulsoni, A., Ferrero, S., Tosti, M. E., Luminari, S., Dondi, A., Cavallo, F., Merli, F., Liberati, A. M., Cenfra, N., Renzi, D., Zanni, M., Boccomini, C., Ferreri, A. J. M., Rattotti, S., Zilioli, V. R., Bolis, S. A., Bernuzzi, P., Musuraca, G., Gaidano, G., … Del Giudice, I. (2024). Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. The Lancet. Haematology, 11(7), e499–e509. https://doi.org/10.1016/S2352-3026(24)00143-1
Chicago
Pulsoni, Alessandro, Simone Ferrero, Maria Elena Tosti, Stefano Luminari, Alessandra Dondi, Federica Cavallo, Francesco Merli, et al. 2024. “Local Radiotherapy and Measurable Residual Disease-Driven Immunotherapy in Patients with Early-Stage Follicular Lymphoma (FIL MIRO): Final Results of a Prospective, Multicentre, Phase 2 Trial.” The Lancet. Haematology 11 (7): e499–509. doi:10.1016/S2352-3026(24)00143-1.